Bambuterol

Jump to: navigation, search
Bambuterol
Bambuterol-2D-skeletal.png
Clinical data
AHFS/Drugs.comInternational Drug Names
Pregnancy
category
  • Unknown
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability20%
MetabolismHepatic, extensive
Further metabolized to terbutaline by plasma cholinesterase
Elimination half-life13 hours (bambuterol)
21 hours (terbutaline)
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC18H29N3O5
Molar mass367.44 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Bambuterol

Articles

Most recent articles on Bambuterol

Most cited articles on Bambuterol

Review articles on Bambuterol

Articles on Bambuterol in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Bambuterol

Images of Bambuterol

Photos of Bambuterol

Podcasts & MP3s on Bambuterol

Videos on Bambuterol

Evidence Based Medicine

Cochrane Collaboration on Bambuterol

Bandolier on Bambuterol

TRIP on Bambuterol

Clinical Trials

Ongoing Trials on Bambuterol at Clinical Trials.gov

Trial results on Bambuterol

Clinical Trials on Bambuterol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Bambuterol

NICE Guidance on Bambuterol

NHS PRODIGY Guidance

FDA on Bambuterol

CDC on Bambuterol

Books

Books on Bambuterol

News

Bambuterol in the news

Be alerted to news on Bambuterol

News trends on Bambuterol

Commentary

Blogs on Bambuterol

Definitions

Definitions of Bambuterol

Patient Resources / Community

Patient resources on Bambuterol

Discussion groups on Bambuterol

Patient Handouts on Bambuterol

Directions to Hospitals Treating Bambuterol

Risk calculators and risk factors for Bambuterol

Healthcare Provider Resources

Symptoms of Bambuterol

Causes & Risk Factors for Bambuterol

Diagnostic studies for Bambuterol

Treatment of Bambuterol

Continuing Medical Education (CME)

CME Programs on Bambuterol

International

Bambuterol en Espanol

Bambuterol en Francais

Business

Bambuterol in the Marketplace

Patents on Bambuterol

Experimental / Informatics

List of terms related to Bambuterol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Bambuterol is a long acting beta-adrenoceptor agonist (LABA) used in the treatment of asthma; it also is a prodrug of terbutaline. Commercially, the AstraZeneca pharmaceutical company produces and markets bambuterol as Bambec and Oxeol (INN).[1]

Indications

As other LABAs, bambuterol is used in the long-term management of persistent asthma.[1] It should not be used as a rescue medication for short-term relief of asthma symptoms.

Contraindications

Bambuterol is contraindicated in pregnancy and in people with seriously impaired liver function. It can be used by people with renal impairment, but dose adjustments are necessary.[1]

Adverse effects

The adverse effect profile of bambuterol is similar to that of salbutamol, and may include fatigue, nausea, palpitations, headache, dizziness and tremor.[1]

Interactions

Concomitant administration of bambuterol with corticosteroids, diuretics, and xanthine derivatives (such as theophylline) increases the risk of hypokalemia (decreased levels of potassium in the blood).[2]

Bambuterol acts as a cholinesterase inhibitor, and can prolong the duration of action of suxamethonium (succinylcholine) and other drugs whose breakdown in the body depends on cholinesterase function.[1] Butyrylcholinesterase activity returns to normal approximately two weeks after bambuterol is stopped.[3] It can also enhance the effects of non-depolarizing neuromuscular blockers, such as vecuronium bromide.[2]

References

  1. 1.0 1.1 1.2 1.3 1.4 Sweetman, Sean C., ed. (2009). "Bronchodilators and Anti-asthma Drugs". Martindale: The complete drug reference (36th ed.). London: Pharmaceutical Press. pp. 1115–16. ISBN 978-0-85369-840-1.
  2. 2.0 2.1 Sweetman (2009), pp. 1132–33.
  3. Sitar DS (October 1996). "Clinical pharmacokinetics of bambuterol". Clin Pharmacokinet. 31 (4): 246–56. doi:10.2165/00003088-199631040-00002. PMID 8896942.

Linked-in.jpg